Your browser doesn't support javascript.
loading
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG).
Schröder, Carolien P; van Leeuwen-Stok, Elise; Cardoso, Fatima; Linderholm, Barbro; Poncet, Coralie; Wolff, Antonio C; Bjelic-Radisic, Vesna; Werutsky, Gustavo; Abreu, Miguel H; Bozovic-Spasojevic, Ivana; den Hoed, Irma; Honkoop, Aafke H; Los, Maartje; Leone, Jose P; Russell, Nicola S; Smilde, Tineke J; van der Velden, Annette W G; Van Poznak, Catherine; Vleugel, Marije M; Yung, Rachel L; Coens, Corneel; Giordano, Sharon H; Ruddy, Kathryn J.
Afiliación
  • Schröder CP; Department Medical Oncology, Netherlands Cancer Institute Amsterdam and University Medical Center Groningen, The Netherlands.
  • van Leeuwen-Stok E; Dutch Breast Cancer Trialists' Research Group (BOOG), The Netherlands.
  • Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
  • Linderholm B; Department of Oncologym, Sahlgrenska University Hospital, Gothenburg, Sweden and Swedish Association of Breast Oncologists (SABO), Sweden.
  • Poncet C; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Wolff AC; Department of Medical Oncology, Johns Hopkins, Baltimore, MD, USA.
  • Bjelic-Radisic V; Breast Unit, Helios University Clinic, Wuppertal, University Witten/Herdecke, Germany.
  • Werutsky G; Latin American Cooperative Oncology Group, Porto Alegre, Brazil.
  • Abreu MH; Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal.
  • Bozovic-Spasojevic I; Department of Medical Oncology, Institute of Oncology and Radiology, Belgrade, Serbia.
  • den Hoed I; Department of Medical Oncology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands.
  • Honkoop AH; Department of Medical Oncology, Isala, Zwolle, The Netherlands.
  • Los M; Department of Medical Oncology, St. Antonius Ziekenhuis, Utrecht, The Netherlands.
  • Leone JP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Russell NS; Department of Radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis's Hertogenbosch, The Netherlands.
  • van der Velden AWG; Department of Medical Oncology, Martini Ziekenhuis, Groningen, The Netherlands.
  • Van Poznak C; Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Vleugel MM; Department of Medical Oncology, Waterlandziekenhuis, Purmerend, The Netherlands.
  • Yung RL; Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Coens C; European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
  • Giordano SH; Department of Health Services Research and Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Oncologist ; 28(10): e877-e883, 2023 10 03.
Article en En | MEDLINE | ID: mdl-37310797
ABSTRACT

INTRODUCTION:

Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program.

METHODS:

Questionnaires at BC diagnosis included the EORTC QLQ-C30 and BR23 (BC specific module), adapted for men. High functioning and global health/QoL scores indicate high functioning levels/high QoL; high symptom-focused measures scores indicate high symptoms/problems levels. EORTC reference data for healthy men and women with BC were used for comparisons.

RESULTS:

Of 422 men consenting to participate, 363 were evaluable. Median age was 67 years, and median time between diagnosis and survey was 1.1 months. A total of 114 men (45%) had node-positive early disease, and 28 (8%) had advanced disease. Baseline mean global health status score was 73 (SD 21), better than in female BC reference data (62, SD 25). Common symptoms in male BC were fatigue (22, SD 24), insomnia (21, SD 28), and pain (16, SD 23), for which women's mean scores indicated more burdensome symptoms at 33 (SD 26), 30 (SD 32), and 29 (SD 29). Men's mean sexual activity score was 31 (SD 26), with less sexual activity in older patients or advanced disease.

CONCLUSIONS:

QoL and symptom burden in male BC patients appears no worse (and possibly better) than that in female patients. Future analyses on impact of treatment on symptoms and QoL over time, may support tailoring of male BC management.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias de la Mama Masculina Tipo de estudio: Observational_studies Aspecto: Patient_preference Límite: Aged / Child, preschool / Female / Humans / Male Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias de la Mama Masculina Tipo de estudio: Observational_studies Aspecto: Patient_preference Límite: Aged / Child, preschool / Female / Humans / Male Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos